Antiplatelet and antithrombotic treatment after transcatheter aortic valve implantation - Comparison of regimes

Journal of Invasive Cardiology

Volumn 25, Issue 10, 2013, Pages 544-548

  Poliacikova, Petra ^a   Cockburn, James ^a   De Belder, Adam ^a   Trivedi, Uday ^a   Hildick Smith, David ^a  

^a UK   (United Kingdom)

Author keywords

complications; transcatheter aortic valve replacement

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; WARFARIN;

ADULT; AGE DISTRIBUTION; AGED; AORTA STENOSIS; AORTA VALVE REPLACEMENT; ARTICLE; BLEEDING; BODY MASS; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HOSPITAL; HOSPITAL PATIENT; HUMAN; KIDNEY DISEASE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; SCORING SYSTEM; TRANSCATHETER AORTIC VALVE IMPLANTATION; TREATMENT OUTCOME;

AGED, 80 AND OVER; AORTIC VALVE STENOSIS; CARDIAC CATHETERIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; THROMBOSIS; TREATMENT OUTCOME;

EID: 84885462933     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Smith C, Leon M, Mack M, et al. Transcatheter versus surgical aortic valve replacement in high-risk patients. N Engl J Med. 2011;364(23):2187-2198
2. Leon MB, Smith CR, Mack M, et al; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597-1607
3. Kahlert P, Doettger P, Mori K, et al. Cerebral embolization during transcatheter aortic valve implantation: a transcranial Doppler study. Circulation. 2012;126(10):1245-1255
4. Tay EL, Gurvitch R, Wijesinghe N, et al. A high-risk period for cerebrovascular events exists after transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2011;4(12):1290-1297
5. Holmes DR Jr, Mack MJ, Kaul S, et al. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol. 2012;59(13):1200-1254
6. Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the working group on thrombosis of the European Society of Cardiology. Eur Heart J. 2011;32(15):1854-1864
7. Butchart EG, Gohlke-Bärwolf C, Antunes MJ, et al; Working groups on valvular heart disease, thrombosis, and cardiac rehabilitation and exercise physiology, European Society of Cardiology. Recommendations for the management of patients after heart valve surgery. Eur Heart J. 2005;26(22):2463-2471
8. Bonow RO, Carabello BA, Chatterjee K, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;52(13):e1-e142
9. Gherli T, Colli A, Fragnito C, et al. Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study. Circulation. 2004;110(5):496-500
10. Mistiaen W, Van Cauwelaert P, Muylaert P, Sys SU, Harrisson F, Bortier H. Thromboembolic events after aortic valve replacement in elderly patients with a Carpentier-Edwards Perimount pericardial bioprosthesis. J Thorac Cardiovasc Surg. 2004;127(4):1166-1170
11. Noble S, Asgar A, Cartier R, Virmani R, Bonan R. Anatomo-pathological analysis after CoreValve revalving system implantations. EuroIntervention. 2009;5(1):78-85
12. Ussia GP, Scarabelli M, Mulè M, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol. 2011;108(12):1772-1776
13. Stabile E, Sorropago G, Pucciarelli A, et al. SAT-TAVI (Single Antiplatelet Therapy for TAVI) study: a randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. J Am Coll Cardiol. 2011;58(20)Suppl B:B218
14. Tchetche D, Van der Boon RM, Dumonteil N, et al. Adverse impact of bleeding and transfusion on the outcome post-transcatheter aortic valve implantation: insights from the Pooled-RotterdAm-Milano-Toulouse In Collaboration Plus (PRAGMATIC Plus) initiative. Am Heart J. 2012;164(3):402-409
15. Halliday BP, Dworakowski R, Brickham B, Wendler O, MacCarthy P. Usefulness of periprocedural bleeding to predict outcome after transcatheter aortic valve implantation. Am J Cardiol. 2012;109(5):724-728
16. Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol. 2007;50(18):1742-1751